Get the Stockscreener App
0.5968
14.06%
-0.0976
Jaguar Health Inc stock is traded at $0.5968, with a volume of 2.65M.
It is down -14.06% in the last 24 hours and down -40.32% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
See More
Previous Close:
$0.6944
Open:
$0.677
24h Volume:
2.65M
Relative Volume:
22.20
Market Cap:
$2.93M
Revenue:
$29.57M
Net Income/Loss:
$-34.68M
P/E Ratio:
-0.000842
EPS:
-708.7214
Net Cash Flow:
$-7.58M
1W Performance:
-26.31%
1M Performance:
-40.32%
6M Performance:
-97.40%
1Y Performance:
-98.86%
1-Day Range:
$0.5716
$0.6808
1-Week Range:
$0.5716
$0.825
52-Week Range:
$0.5716
$77.63
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.5968 | 4.29M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Form 424B3 Jaguar Health, Inc. - StreetInsider
Jaguar Health | 424B3: Prospectus - Moomoo
Jaguar Health revenue falls 59% to $1.2 million - grafa.com
Jaguar Health | 10-Q: Quarterly report - Moomoo
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and Strategic Pivot - GuruFocus
Jaguar Health (JAGX) Shifts Focus to Rare GI Treatments Amid Cha - GuruFocus
Jaguar Health presents crofelemer data at ESPGHAN 2026 - scanx.trade
Jaguar Health Sets Q2 2027 NDA Submission Timeline for MVID Treatment - Minichart
Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Jaguar Health Posts Q2 Total Revenue $1.2 Million, EPS $-15.68 - TradingView
Jaguar Health Q2 loss narrows 96% as revenue falls 59% on licensing shift - scanx.trade
Q2 2026 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health Reports $1.2 Million Q2 Revenue and $12.7 Million Net Loss - Quiver Quantitative
Jaguar Health Reports Second Quarter 2026 Financials - ACCESS Newswire
Jaguar Health to hold Q2 2026 investor webcast on August 19 - scanx.trade
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates - Yahoo Finance
JAGX Q2'26 Earnings: EPS estimate is (52.15) USD - TradingView
Jaguar Health, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Jaguar Health Delays Quarterly SEC Filing - TipRanks
Jaguar Health (JAGX) cites major subsequent events in delaying Q2 2026 10-Q - Stock Titan
Jaguar Health (JAGX) details 40.9M-share resale tied to $40M equity line - Stock Titan
Jaguar Health (JAGX) Ticks Up 2.22% to $0.96, Approaching Key Resistance at $1.01Analyst Downgrade Signals - dars.gov.et
Jaguar Health (JAGX) Secures $2 Million Holdback Payment from Fu - GuruFocus
Why is Jaguar Health stock gaining today? - Investing.com
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-08-05 - TradingView
After 12 Months, Crofelemer Cut Support Up to 48% in One MVID Patient - Stock Titan
Why is Jaguar Health stock gaining today? By Investing.com - Investing.com Australia
Jaguar Health (JAGX) Consolidates at $1.0: Support and Resistance Define Trading RangeMcClellan Summation - dars.gov.et
Jaguar Health (JAGX) Holds at $1.00 as Tight Trading Range Defines Key Levels to WatchInstitutional Buy Signals - Vinanet
Jaguar Health (JAGX) Dips 3.56% to $1.00, Pressing Key Support LevelSector Neutral Pair - Vinanet
Jaguar Health (JAGX) Highlights Market Potential of Neonorm Dog Amidst Challenging Valuation - GuruFocus
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - Yahoo! Finance Canada
Jaguar Health finds strong market interest in N... - Pluang
Jaguar Health Inc (JAGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jaguar Health Inc (JAGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jaguar Health, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) - ACCESS Newswire
TradingKey - TradingKey
Jaguar Health Inc. (JAGX) Q1 2026 Earnings: Significant Earnings Miss Amid Absent RevenueConsensus Miss Rate - dars.gov.et
Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investors - Stock Titan
JAGX Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Revenue Not ReportedDividend Increase Stocks - Vinanet
Jaguar Health (JAGX) Secures Compassionate Use for Crofelemer in EU - GuruFocus
Jaguar Reports Up to 48% Lower Weekly Support in One MVID Patient - Stock Titan
Jaguar Health (JAGX) Registration filing Summary - Quartr
Jaguar Health (JAGX) Holds at $1.30 as Support Test Looms – What’s Next?Vanna Flow - dars.gov.et
Jaguar Health Company Profile & Introduction - Moomoo
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Form S-1 Jaguar Health Inc For: 16 July By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health (NASDAQ: JAGX) plans 5.5M-share resale registration - Stock Titan
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):